
Here's How Much A 2021 Ford Mustang Mach 1 Has Depreciated In 5 Years
The track-focused Mach 1 has hit the five-year mark. Here's what you can expect to pay for a used 2021 model in August 2026.
Credence Wire Journalist
Biotech & Life Sciences Reporter
Reports on CRISPR, longevity science, synthetic biology, and the coming convergence of AI and drug discovery. Based in San Francisco.

The track-focused Mach 1 has hit the five-year mark. Here's what you can expect to pay for a used 2021 model in August 2026.

The retail giant's new device bundle includes a 2-in-1 laptop and tablet, plus a 7-piece accessories kit, at a price that undercuts rivals.

The next Ultra Watch arrives next month with a blood pressure sensor, a micro-LED display, and a chip that could double battery life. Here's why I'm ready to buy.

The company's annual iPhone event is set for next month, with at least five new devices expected, and a few surprises possible.

Fervo Energy and Crusoe commissioned a 50-megawatt Nevada plant routing enhanced geothermal power directly to GPU clusters.

A wireless intracortical array decoded intended sentences at 62 words per minute with 91 percent accuracy in a study of four participants with ALS and brainstem stroke.

Biotech startup HemoSynthetix receives regulatory approval for clinical testing of a stable, long-shelf-life protein matrix.

Melanoma patients receiving the individualized therapy alongside checkpoint inhibitors showed a 44 percent reduction in recurrence risk over three years in a trial of 1,100 participants.

A Phase III trial of 340 patients across 12 centers shows that a single infusion of the CRISPR-edited therapy results in sustained elevation of fetal hemoglobin in 97.3% of participants, eliminating vaso-occlusive crises in the majority of patients.

Researchers have used AlphaFold 3 to computationally design protein structures that selectively induce apoptosis in pancreatic cancer cell lines, a breakthrough that could reshape oncology drug pipelines.
Free Morning Briefing
A calm, intelligent briefing delivered daily before the market opens.
Free. No spam. Unsubscribe anytime.